Teva Pharmaceuticals Sustainability Profile
Teva Pharmaceuticals Industries Ltd., commonly known as Teva, is a global leader in the pharmaceutical industry, headquartered in Israel (IL). Founded in 1901, Teva has established a strong presence in over 60 countries, focusing on the development, production, and marketing of generic and specialty medicines. With a diverse portfolio that includes a wide range of therapeutic areas such as central nervous system disorders, oncology, and respiratory conditions, Teva is renowned for its commitment to accessibility and innovation. The company’s core products, including the widely used Copaxone and a robust selection of generic medications, set it apart in a competitive market. Teva's notable achievements include being one of the largest generic drug manufacturers globally, reflecting its significant market position and dedication to improving patient outcomes through affordable healthcare solutions.
DitchCarbon Score
How does Teva Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Teva Pharmaceuticals's score of 85 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Teva Pharmaceuticals's reported carbon emissions
In 2024, Teva Pharmaceuticals reported total greenhouse gas (GHG) emissions of approximately 4,406,116,000 kg CO2e globally. This figure includes 243,603,000 kg CO2e from Scope 1 emissions, 218,504,000 kg CO2e from market-based Scope 2 emissions, and a significant 4,066,116,000 kg CO2e from Scope 3 emissions. The company has set ambitious targets to reduce its absolute Scope 1 and 2 GHG emissions by 25% by 2025 and by 46% by 2030, using 2019 as the baseline year. Additionally, Teva aims to cut its absolute Scope 3 emissions by 25% by 2030, with a 2020 baseline. Teva's commitment to sustainability extends to a long-term goal of achieving net-zero emissions across its operations and value chain by 2045. This commitment aligns with the Science Based Targets initiative (SBTi), which has validated Teva's targets as consistent with the reductions required to limit global warming to 1.5°C. The company has made notable progress, having already achieved a 43% reduction in Scope 1 and 2 emissions compared to 2019, surpassing its 2025 target two years ahead of schedule. Teva's emissions data and reduction initiatives are sourced from its corporate family, specifically Teva Pharmaceutical Industries Limited, ensuring a comprehensive approach to its climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 438,420,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 613,541,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Teva Pharmaceuticals's Industry?
How Carbon Intensive is Teva Pharmaceuticals's Location?
Teva Pharmaceuticals's Scope 3 Categories Breakdown
Teva Pharmaceuticals's Scope 3 emissions, which decreased by 6% last year and decreased by approximately 24% since 2020, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 61% of Scope 3 emissions.
Top Scope 3 Categories
Teva Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Teva Pharmaceuticals has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Teva Pharmaceuticals's sustainability data and climate commitments